Technion Scientist Reveals Breakthrough in Treating Parkinson's And
Alzheimer's Diseases
PHILADELPHIA, Jan. 31 /PRNewswire/ -- Technion Professor Moussa Youdim, an
internationally-acclaimed expert in the treatment of neuro-degenerative
disorders such as Alzheimer's and Parkinson's, and the developer of
revolutionary drugs for these diseases, will present his findings to the
public on Sunday, February 4th at 11:30 am at Johnny Mott's Restaurant,
Cedarbrook Hill Apartments, Building A, in Wyncote, PA. The event will be
hosted by the Greater Philadelphia Chapter of the American Technion Society.
Prof. Youdim's work at the Eve Topf Neuro-Degenerative Disease Research
and Teaching Center at the Technion-Israel Institute of Technology has led to
the development of new drugs and technologies that are believed to halt the
progress of Parkinson's by stopping the death of brain cells. It is believed
that the death of these cells causes the disease.
Prof. Youdim's new drug, called Rasagiline, has been shown to halt the
death of neurons, and has exhibited remarkable improvement in the
physiological, behavioral and biochemical tests when used in laboratory
animals. It is currently undergoing the final test in preparation for Food
and Drug Administration (FDA) approval for the treatment of Parkinson's
disease.
In 1991, Prof. Youdim introduced another drug, Deprenyl, that slows the
progress of Parkinson's. Prof. Youdim holds the Minnie and Ruben Finkelstein
Chair of Life Sciences at the Technion. His distinguished career also
includes positions as chairman of the Pharmacology Department at the Technion
Faculty of Medicine.
Coverage is invited. For more information or to make reservations call
610-667-6777.
Based in New York City, the American Technion Society is the leading
American organization supporting higher education in Israel, with more than
20,000 supporters and 17 offices around the country. Technion societies are
located in 24 countries around the world.
SOURCE American Technion Society
